William Blair analyst Tim Lugo reiterated an Outperform rating on Revance Therapeutic (NASDAQ: RVNC).The analyst comments "Revance announced first quarter ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Revance Therapeutic (RVNC) PT Lowered to $8 at Goldman SachsMay 13, 2024 6:15 AM Revance Therapeutic (RVNC) PT Lowered to $11 at Piper SandlerMay 10, 2024 8:18 AM Revance Therapeutic (RVNC) PT Lowered to $11 at H.C. WainwrightMay 10, 2024 6:55 AM Revance Therapeutic (RVNC) PT Lowered to $12 at NeedhamMay 10, 2024 6:43 AM Revance Therapeutic (RVNC) PT Lowered to $8 at MizuhoMay 10, 2024 6:39 AM Revance Therapeutics (RVNC) Misses Q1 EPS by 3c, provides outlookMay 9, 2024 4:38 PM Form 10-Q Revance Therapeutics, For: Mar 31May 9, 2024 4:34 PM Form 8-K Revance Therapeutics, For: May 09May 9, 2024 4:11 PM Revance Therapeutics (RVNC) Expands into US Market with the Launch of DAXXIFYMay 9, 2024 4:07 PM Revance Reports First Quarter 2024 Financial Results, Provides Corporate UpdateMay 9, 2024 4:06 PM Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical DystoniaMay 9, 2024 4:05 PM